Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$5.41 - $6.74 $2.96 Million - $3.68 Million
-546,607 Reduced 89.66%
63,047 $323,000
Q2 2022

Aug 15, 2022

SELL
$2.18 - $6.39 $392,260 - $1.15 Million
-179,936 Reduced 22.79%
609,654 $3.82 Million
Q1 2022

May 16, 2022

SELL
$2.77 - $5.36 $189,758 - $367,186
-68,505 Reduced 7.98%
789,590 $2.8 Million
Q4 2021

Feb 14, 2022

BUY
$4.71 - $7.38 $163,498 - $256,181
34,713 Added 4.22%
858,095 $4.31 Million
Q3 2021

Nov 15, 2021

SELL
$5.2 - $8.42 $22,599 - $36,593
-4,346 Reduced 0.53%
823,382 $6.03 Million
Q2 2021

Aug 16, 2021

BUY
$6.57 - $10.71 $5.44 Million - $8.86 Million
827,728 New
827,728 $7.11 Million

Others Institutions Holding FSTX

About F-star Therapeutics, Inc.


  • Ticker FSTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 21,584,700
  • Description
  • F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck c...
More about FSTX
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.